Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Gazzard

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|September 10, 2002
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?John F Morlese, Nadeem A Qazi, Brian G Gazzard, et al.
European Journal of Gastroenterology & Hepatology|August 19, 2003
Successful treatment of acute haemorrhagic cytomegalovirus colitis with ganciclovir in an individual without overt immunocompromiseShilpan M Patel, Patricia Cohen, Matthew C Pickering, et al.
Blood|April 7, 2006
The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safeDanish Mazhar, Justin Stebbing, Rachel Lewis, et al.
AIDS (London, England)|July 20, 2002
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factorsGraeme J Moyle, Debasis Datta, Sundhiya Mandalia, et al.
BMJ (Clinical Research Ed.)|January 16, 2007
When should antiretroviral therapy for HIV be started?Andrew N Phillips, Brian G Gazzard, Nathan Clumeck, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individualsNaa Torshie Annan, Mark Nelson, Sundhiya Mandalia, et al.
Antiviral Therapy|May 28, 2005
Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosisChristos Michailidis, Anton L Pozniak, Sundhiya Mandalia, et al.
Plos One|February 25, 2012
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010Sundhiya Mandalia, Samantha J Westrop, Eduard J Beck, et al.
The Journal of Infectious Diseases|February 18, 2005
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infectionGraeme J Moyle, Adrian Wildfire, Sundhiya Mandalia, et al.
AIDS (London, England)|December 4, 2008
Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individualsJohn Ns Gregson, Alan Steel, Mark Bower, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|September 10, 2002
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?John F Morlese, Nadeem A Qazi, Brian G Gazzard, et al.
European Journal of Gastroenterology & Hepatology|August 19, 2003
Successful treatment of acute haemorrhagic cytomegalovirus colitis with ganciclovir in an individual without overt immunocompromiseShilpan M Patel, Patricia Cohen, Matthew C Pickering, et al.
Blood|April 7, 2006
The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safeDanish Mazhar, Justin Stebbing, Rachel Lewis, et al.
AIDS (London, England)|July 20, 2002
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factorsGraeme J Moyle, Debasis Datta, Sundhiya Mandalia, et al.
BMJ (Clinical Research Ed.)|January 16, 2007
When should antiretroviral therapy for HIV be started?Andrew N Phillips, Brian G Gazzard, Nathan Clumeck, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individualsNaa Torshie Annan, Mark Nelson, Sundhiya Mandalia, et al.
Antiviral Therapy|May 28, 2005
Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosisChristos Michailidis, Anton L Pozniak, Sundhiya Mandalia, et al.
Plos One|February 25, 2012
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010Sundhiya Mandalia, Samantha J Westrop, Eduard J Beck, et al.
The Journal of Infectious Diseases|February 18, 2005
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infectionGraeme J Moyle, Adrian Wildfire, Sundhiya Mandalia, et al.
AIDS (London, England)|December 4, 2008
Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individualsJohn Ns Gregson, Alan Steel, Mark Bower, et al.
Pageof 5